hsa-mir-877: hsa-mir-877 is a microRNA that has been reported as an oncogene in gastric cancer [PMC7794682]. In nonresponder samples of both lung squamous cell carcinoma (LUSC) and head and neck squamous cell carcinoma (HNSC), hsa-mir-877 was found to be upregulated, along with hsa-miR-130a and hsa-miR-15a [PMC7794682]. Furthermore, in a study on endometrial cancer (EC), hsa-mir-877 was identified as one of the candidate reference genes that showed uniform expression [PMC3531299].

MIR877: MIR877 is a miRNA that has been identified as playing a role in inhibiting the development of pulmonary fibrosis and increasing the levels of the inhibitory protein Smad7 [PMC6957807]. It is a molecular target that may be responsible for the therapeutic effects of CPV in treating respiratory disorders [PMC6957807]. CPV has been found to regulate miRNAs, including MIR877, which are involved in anti-diabetic, anti-fibrotic, and anti-inflammatory activities [PMC6957807]. In animals treated with CPV, down-regulation of MIR877 was observed in the liver [PMC6957807]. In individuals with disrupted CNVs, MIR877 was found to be disrupted along with its target gene ARHGAP26 [PMC3938728]. Additionally, MIR877 has been identified as one of the miRNAs that are more abundant during the G2M phase [PMC8713755]. In a study on primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), a SNP located between PSORS1C3 and MIR877 was strongly associated with PSC [PMC5217265]. Overall, these findings highlight the importance of MIR877 in various biological processes and its potential as a therapeutic target for respiratory disorders and liver diseases.